[Substantion of the reference Values of SCFA in saliva in ratients without upper respiratory tract diseases.]

Biochemical indicators of saliva were studied in 47 patients of the intensive care unit and intensive care unit of a neurosurgical hospital with varying degrees of severity of the disease. The method of gas-liquid chromatography of the acidified substrate of the saliva filtrate determined the concentrations of short-chain fatty acids (SCFA) and their reference values for patients without respiratory tract diseases. The threshold values of the concentrations of SCFA and the values of their calculated indices were determined by ROC analysis with the construction of the ROC curve, calculation of the area under the curve (AUC) and the cutoff threshold CutOff. The method of determining reference values of HFA in saliva developed as a result of the study makes it possible to assess the risks of developing an unfavorable course of the disease, optimize treatment tactics and improve the prognosis of the disease.

[THE EVALUATION OF MICROBIOLOGICAL DISORDERS OF MICROFLORA OF OROPHARYNX AND INTESTINE USING MATHEMATICAL MODELING TECHNIQUE].

The analysis was applied to microflora of feces and oropharinx and concentration of volatile fatty acids in saliva from patients of consultative diagnostic center of G.N. Gabrichevskii Moscow research institute of epidemiology and microbiology. The computer classification program is developed on the basis of determining degree of microbiological disorders on the basis of received data and using artificial neural networks and discriminant analysis. The analysis established decreasing of probability of false classification in case of increasing of degree of microbiological disorders of microflora of intestine and absence of such a correlation for microbiological and metabolic disorders of microflora of intestine.

[Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].

The data on cytotoxicity and antiviral activity of commercial antivirals, such as Remantadine, Oseltamivir, Arbidol and Ribavirin in the MDCK cell culture infected with highly pathogenic (H5N1) and pandemic 2009 (H1N1) influenza A viruses are presented. The study of the antiviral activity of antivirals in the MDCK cells culture demonstrated that Arbidol, Rimantadine and Ribavirin efficiently inhibited reproduction of the highly pathogenic H5N1 influenza viruses isolated from sick birds. Arbidol and Oseltamivir carboxylate selectively inhibited reproduction of the pandemic 2009 H1N1 influenza A viruses with changed specificity to the cell receptors, causing severe influenza in men, while remantadine had no effect on their reproduction.

[Study of the antiviral activity of Russian anti-influenza agents in cell culture and animal models].

The study of the antiviral activity of Russian anti-influenza agents in the cultured MDCK cells demonstrated that arbidol and ribavirin inhibited the reproduction of various influenza A virus strains, including rimantadine- and ozeltamivir-resistant variants, as well as influenza B viruses (IC50 2-8.5 microg/ml). Rimantadine at concentrations of 1-5 microg/ml completely inhibited the reproduction of reference and ozeltamivir-resistant influenza A virus strains, and it had no effect on the reproduction of influenza B viruses and rimantadine-resistant influenza A viruses. Arbidol and ribavirin also inhibited the reproduction of pandemic influenza A/California/04/2009(H1N1), A/California/07/2009(H1N1), and A/Moscow/01/2009(H1N1)swl viruses in the cultured MDCK cells (IC50 = 1.5-4.0 microg/ml) while rimantadine had no effect on their reproduction. The cultured cells showed no significant antiviral activity of ingavirin at nontoxic concentrations (up to 200 microg/ml) against all study strains of influenza A and B viruses, including pandemic A(H1N1) influenza virus strains. The activity of rimantadine, arbidol, and ingavirin was found on a model of Influenza pneumonia in mice infected with their adopted influenza A/Aichi/2/69(H3N2) virus. The preventive efficacy of the three test agents was similar and most pronounced when they were used 96 hours before infection, by preventing 40-50% death in the animals and their body weight loss and by increasing their survival by 1.3-1.5 times. Arbidol and rimantadine were more effective when used for treatment and prophylaxis in doses of 30 and 10 mg/kg/day, respectively, by protecting the infected animals from 60-80% death, increasing their survival by 1.7-2 times, and preventing their body weight loss as compared with the control. The same experiments with ingavirin showed that this agent was less effective than arbidol and rimantadine. Thus, arbidol and rimantadine have a pronounced antiviral infection in both cell culture and a model of influenza pneumonia. The found efficacy of ingavirin on an integral model of murine influenza pneumonia without its activity in the cultured cells is likely to be due to other pharmacological properties of the drug rather than its direct virus-specific action.